American Journal of Pharmacology and Pharmacotherapeutics

CA-RT-CURDA-Cannabis Abuse, Research lost its Translation, Correction for future appropriate Use through the Research and Data Analysis

Medical Events 2022
March 28, 2022 | Webinar

Antonio Steardo

Italy

Keynote: J Pharmacol Pharmacother

Abstract

During passed decades research have been retrieving the components of cannabis making feasible the study of several psychotropic and non-psychotropic compounds that this herb and its variants contain. Unfortunately, as it seems the studies passed from the bench to the wrong side of the market. Useful retrieved data didn’t get close to new pharmaceutical products only, but also to free taste products, enhancing in this way, the abuse of Cannabis sativa and all its variants. By this point the study aims to create a prospective on Pharmacovigilance to control properly the abuse of cannabis and its derivate. Indeed, passed collected data can delineate a strategy for a correct prevision. Knowledge and management of its nasty side effects are a step forward on public health to manage cannabis addiction. The aim of this study is not only to create an appropriate pharmacovigilance asset but even to set new data analysis for the appropriate use of cannabis which had to be a new molecular therapeutic lead. It has gone lost during biochemical translation of data to the applied research.

Biography

Doctor Antonio Steardo specialized in Pharmacology and graduated in Pharmacy and Pharmaceutical Chemist. He has now gained years of experience since 2002 in the pharmaceutical products trade sector as he could have been behind the counter of the Steardo pharmacy from an early age. Already in elementary school, the curiosity for chemistry manifests itself during his games and continues lectures at the department of science at the University of Salerno. Therefore, during the cycle of studies, he prefers biochemistry and biochemistry of drug action, graduating in July 2007 with a thesis on the functioning of the endocannabinoid system on Alzheimer’s disease in pharmacology. Following the beginning of his pharmaceutical chemistry studies, he stopped for a competition as a postgraduate in pharmacology at the University of Rome La Sapienza in July 2014. Expecting constant improvement as a professional update, he enrolled in the continuing professional training department at the University of Oxford to follow courses in Experimental and Translation Therapy and on Medical Research. His desire to improve leads him to attend international conferences and seminars.